Tyler J Nielsen

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer immunology, immunotherapy : CII

NPJ breast cancer

Cancers

Insight Genetics (United States)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Insight Genetics (United States) Jun 01 2013

United States

Staff Scientist

Publications

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S Seitz, Tyler J Nielsen, Marc Thill, Antonio Antón-Torres, Stefania Russo, Eva Ciruelos Gil, Brock L Schweitzer, Douglas Teller Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Gyorffy Balazs, Marco Colleoni, Catherine M Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Blasi, Maurizio Callari, Lajos Pusztai, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Tyler J Nielsen, Matthew Gordon Varga, Catherine T Cronister, Brian Z Ring, Robert S Seitz, Douglas T Ross, Brock L Schweitzer, Kimberly McGregor
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort. Cancer immunology, immunotherapy : CII (2023)
Carlotta Antoniotti, Alessandra Boccaccino, Robert S Seitz, Mirella Giordano, Aurelie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J Nielsen, Jerome Galon, Matthew Gordon Varga, Brock L Schweitzer, Chiara Cremolini
An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
David B Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L Redmond, Maritza Martel, Zhaoyu Sun, Mary B Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S Seitz, Tyler J Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J Urba, Heather L McArthur
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer. NPJ breast cancer 9 (1) (2023)
Toshiaki Iwase, Kim R M Blenman, Xiaotong Li, Emily Reisenbichler, Robert Seitz, David Hout, Tyler J Nielsen, Brock L Schweitzer, Daniel B Bailey, Yichao Shen, Xiang Zhang, Lajos Pusztai, Naoto Tada Ueno
A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers 13 (19) (2021)
Jose Rodrigo Espinosa Fernandez, Bedrich L Eckhardt, Jangsoon Lee, Bora Lim, Troy Pearson, Robert S Seitz, David R Hout, Brock L Schweitzer, Tyler J Nielsen, O Rayne Lawrence, Ying Wang, Arvind Rao, Naoto Tada Ueno
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PloS one 15 (4) (2020)

Tyler J Nielsen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Tyler J Nielsen